



CURE
CANCER
AUSTRALIA FOUNDATION

2014
YEAR IN
REVIEW

CURE CANCER PROVIDES FUNDING TO AUSTRALIA'S BRIGHTEST EMERGING CANCER RESEARCHERS

Each year we carefully select an outstanding group of researchers and provide them with essential funds to investigate their groundbreaking ideas to fight all types of cancer. We fund the smartest scientists, early in their careers, when different ideas and challenging perspectives burn brightest.

We've made great strides in cancer detection, treatment and survival, but far too many lives are still destroyed by cancer. More Australians than ever before are being diagnosed with cancer each year.

It's critical we continue to invest in research. There's much to do, but by working together, we can cure cancer.

MESSAGE FROM MAX GOSLING, CHAIRMAN

The Cure Cancer Australia Foundation specifically funds high calibre early career researchers, providing vital start-up funds for innovative, ground breaking research projects across all types of cancer. We place a high importance on providing 'seed funding' to researchers early in their careers because we believe in supporting new and fresh thinking in the cancer research field.

Our aim is to fund projects identified by the wider research community, as the most promising in their potential to cure cancer.

Our funding covers research investigation across all forms of cancer, in all states of Australia, in major research institutes, hospitals, and universities. By partnering with the Priority-driven Collaborative Cancer Research Scheme (PdCCRS), which is administered by Cancer Australia, we fund bright, emerging researchers who have been selected via the National Health and Medical Research Council (NHMRC)'s rigorous and well-respected peer-review process.

Over the last three years, Cure Cancer has invested in 96 grants for researchers around Australia. And by collaboratively funding with Cancer Australia, the National Breast Cancer Foundation, Prostate Cancer Foundation, and the Leukaemia Foundation, Cure Cancer ensures continuity of funding for researchers, and efficiency for every dollar donated.

I would like to especially thank our supporters for the donations they continue to make, which enables Cure Cancer to move ahead in its research program. Individual donors and fundraisers, corporate giving, fundraising event participation, Can Too participants, sponsors, Centurions – you all make Cure Cancer and its future possible. My sincerest thanks to you all!

Thanks also to the small, dedicated and committed team of staff and volunteers who drive and co-ordinate our efforts on a daily basis.

We are pleased with what we have achieved, but we know our most important milestone will be when we have made cancer a manageable disease, and have lessened its life threatening impact on families across Australia.

Max Gosling



THE CAN TOO FOUNDATION




In celebrating its tenth year, Can Too made the decision to become a Foundation in its own right. From October 1st 2014, Can Too became The Can Too Foundation - A Health Promotion Foundation, with its own approved DGR (deductible gift recipient) status that raises money for cancer research.

Cure Cancer remains Can Too's major beneficiary and will now be referred to as Cure Cancer's Principal Supporter.

Congratulations to Annie Crawford who is Chair of the new Can Too Foundation, and Susannah Miall who is CEO. Cure Cancer looks forward to many more years ahead of working with Can Too towards a shared vision of a world without cancer.

CURE CANCER RESEARCHER BREAKTHROUGHS IN 2014



Dr David Ziegler

CHILDHOOD CANCER - NEUROBLASTOMA

Dr David Ziegler received a Cure Cancer grant in 2011 and is now leading a groundbreaking clinical trial for neuroblastoma – the most common solid tumour to affect infants and young children.

The clinical trial offers a new treatment for children diagnosed with relapsed neuroblastoma. The trial uses an existing small molecule drug, called Difluoromethylornithine (DFMO), previously used for treating African Sleeping Sickness. Research has shown that DFMO, when used in combination with modern chemotherapy, attacks neuroblastoma much more effectively than chemotherapy drugs alone.

The trial is particularly important as children with high-risk neuroblastoma who relapse after initial treatment are currently considered incurable. It is hoped that by the time the trial concludes in two years, there will be a viable treatment option for children with relapsed neuroblastoma.

Dr David Ziegler is Paediatric Oncologist for the Kids Cancer Centre at Sydney Children's Hospital and Group Leader of Targeted Therapies Program at Children's Cancer Institute.



Dr Bryan Day

BRAIN CANCER - GLIOBLASTOMA

Dr Bryan Day led research at the QIMR Berghofer Medical Research Institute that has resulted in a clinical trial for patients with glioblastoma, the most common form of adult brain cancer. Bryan has received funding grants from Cure Cancer in 2012 and 2015.

The clinical trial involves treating patients with an antibody that targets a protein found on the surface of brain cancer cells.

To date, most new drugs tested for glioblastoma have returned disappointing results and patients have very few treatment options. Glioblastoma is almost always fatal and results in the death of about 1,000 Australians every year. If this trial is successful, it will have an immediate impact by giving patients access to an innovative treatment which has shown great potential in laboratory testing.

The trial is a collaborative effort between scientists at QIMR Berghofer Medical Research Institute, the Ludwig Institute for Cancer Research and Monash University. 2014 Cure Cancer research recipient Hui Gan, is also participating in the trial.



Dr Liesel Fitzgerald

PROSTATE CANCER

Liesel Fitzgerald received funding from Cure Cancer in 2013 for her research into prostate cancer. Liesel's research findings may lead to fewer men with prostate cancer undergoing unnecessary surgery if they are validated and introduced into clinical practice.

Currently only a minority of Australian prostate cancer cases lead to death, but there is no way for doctors to accurately predict which cancers will become lethal. This results in many patients undergoing unnecessary surgery to remove the prostate.

In a paper co-authored by Liesel, three promising tissue biomarkers have been identified that separate men at higher risk of dying from prostate cancer, from those at low risk.

If this preliminary research is validated, it will assist both doctors and patients in understanding whether a tumor is likely to progress and make more informed decisions on whether it is necessary to undergo surgery.



Dr Phoebe Phillips


PRESIDENT, AUSTRALIAN SOCIETY FOR MEDICAL RESEARCH

Dr Phoebe Phillips has been appointed the 2015 President of the Australian Society for Medical Research (ASMR). The ASMR is the peak professional society representing Australian health and medical research, with more than 120,000 members and affiliates in Australia.

Phoebe is head of the Pancreatic Cancer Translational Research Group at the UNSW Lowy Cancer Research Centre. She received funding grants from Cure Cancer in 2009 and 2012 for her research into pancreatic cancer.


Her prestigious appointment as President of the ASMR will see her promoting investment into health and medical research at a time of increasing funding uncertainty in the sector. Phoebe will meet regularly with the Prime Minister, senators, health ministers and politicians as well as funding bodies to advocate for the critical importance of medical and health research.

PROJECTS FUNDED 1967-2014



Cure Cancer has invested over \$24.5 million in 453 cancer research funding grants since 1967. The large investment into blood cancer research can be attributed to the origins of Cure Cancer. The Leo & Jenny Leukaemia and Cancer Foundation was established by two families who were impacted by the death of Leo Byrne and Jenny Landahl, who both sadly died of leukaemia. The Leo & Jenny Leukaemia and Cancer Foundation changed its name to Cure Cancer Australia Foundation in 2002.


2014 REVENUE – \$3.5m



STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 31ST DECEMBER 2014

	2014	2013	2012 \$
REVENUE			
Operating Revenue	3,401,833	3,991,764	4,794,906
Interest Income	124,517	201,470	266,709
TOTAL REVENUE	3,526,350	4,193,234	5,061,615
EXPENSE			
Cost of Programs	1,547,841	1,284,405	1,161,981
Employee Expenses	379,981	456,885	411,355
Operating Expenses	383,503	262,354	202,687
TOTAL EXPENSES	2,311,325	2,003,644	1,776,023

PROJECTS FUNDED 2014



28 young researchers were awarded a Cure Cancer grant in 2014, covering nine different types of cancer. This represents a \$2.6 million of investment in cancer research.

Cure Cancer supports cancer research projects that focus on investigating the cause, prevention and treatment of all types of cancers. The projects selected are considered the most likely to succeed based on their scientific merit as opposed to cancer type, which leads to more researcher dollars being directed to a wide range of cancers.

Company details

CFN 13834N (NSW)

CH1389 (QLD)

20413 (WA)

932 (SA)

ACN 002 838 495

ABN 13 002 838 495

DGR 46730

Cure Cancer Australia Foundation
is a public company limited by
guarantee.

Street address

Level 6, 15-17 Young Street,
Sydney NSW 2000

T 1300 134 567

+61 2 8072 6188

F +61 2 8072 6199

E info@curecancer.org.au

www.curecancer.org.au



Sincere thanks to Proactive Graphics for their support
in the creation of this document.